Senate Biosimilars Bill May Create Exclusivity For Pediatrics And Extra Indications, PhRMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sponsors are committed to firm 12 years of exclusivity, but evergreening remains an obstacle to reintroduction.
You may also be interested in...
FOBs Must Follow The Senate’s Health Reform Pathway; Placeholder Is Key
The state of the congressional debate on follow-on biologics legislation is probably best expressed by the first line on the topic from the most prominent bill: "[Policy under discussion].
FOBs Must Follow The Senate’s Health Reform Pathway; Placeholder Is Key
The state of the congressional debate on follow-on biologics legislation is probably best expressed by the first line on the topic from the most prominent bill: "[Policy under discussion].
Follow-On Biologics Legislation Faces Tough Road Ahead; Momentum Stalled
Prospects for enactment of follow-on biologics legislation appear limited in the near term, according to Capitol Hill players in the debate